cawera.blogg.se - Cost of praxbind

Approval: 2015 -RECENT MAJOR CHANGES- Dosage and Administration, Recommended Dose (2.1) 10/2021 Dosage and Administration, Preparation (2. PRAXBIND® (idarucizumab) injection, for intravenous use Initial U.S. Reprinted with permission by First Databank, Inc. See full prescribing information for PRAXBIND.

WAC = wholesaler acquisition cost or manufacturer’s published price to wholesalers WAC represents a published catalogue or list price and may not represent an actual transactional price.

Approximate wholesale acquisition cost (WAC).

A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial.

Edoxaban (Savaysa) – the fourth new oral anticoagulant.

In one study, approximately 20 of patients required a second dose, doubling the cost.

Given the high cost of idarucizumab, hospitals in geographic proximity. Dabigatran etexilate (Pradaxa) - a new oral anticoagulant. Idarucizumab costs 3,662 for a single treatment (i.e., two infusions). Idarucizumab, an antidote for dabigatran, was recently approved for use in Canada.